Mitragyna speciosa is a tropical evergreen tree in the coffee family, native to Southeast Asia. The plant is more commonly known by its Thai name, kratom. For several centuries it was used regionally as a stimulant during long manual labour shifts and as a folk remedy for various ailments. Over the last fifteen years, it has moved out of that regional context and become a substantial global commercial market driven primarily by online retail in the United States and parts of Europe.
The pharmacology is what has driven both the consumer interest and the regulatory scrutiny. Kratom leaves contain more than forty alkaloids, of which mitragynine and 7-hydroxymitragynine are the two best-characterised. Both interact with mu-opioid receptors in the brain through a different binding profile than classical opioids. At low doses, the effect is broadly stimulant-like, often compared to coffee in subjective feel. At higher doses, the effect shifts toward sedation and analgesia.
The U.S. National Institute on Drug Abuse summarises the published research on these mechanisms and notes that the evidence base remains incomplete by the standards typically applied to medications.
The forms encountered consumer-side
Three forms dominate the consumer market.
Whole-leaf material represents the traditional preparation, with alkaloid concentrations of 1 to 2 percent by weight and significant variation by region of origin and harvest.
Kratom powder is dried, milled leaf material packaged for measured use as a tea, capsule, or powder dose. It carries moderate unit prices and is the format around which most consumer-facing brands have built their product ranges.
Extract products concentrate the alkaloid fraction by removing plant matter, producing material several times more potent by weight. Extracts have grown disproportionately in recent years, and regulatory bodies have flagged the extract category as the subset most associated with concerning adverse-event reports.
What public health authorities currently say
The U.S. Food and Drug Administration has issued multiple consumer advisories on kratom since 2016, citing concerns about contamination, batch-to-batch variability in alkaloid content, and the lack of FDA approval for any therapeutic claim. The Drug Enforcement Administration proposed scheduling mitragynine and 7-hydroxymitragynine in 2016 and withdrew the proposal following public comment. State-by-state legality varies. The U.K. position is different: mitragyna speciosa is captured under the Psychoactive Substances Act 2016, which prohibits production, supply, and importation for human consumption.
The clinical literature on PubMed documents dependence with chronic use, withdrawal symptoms on discontinuation, hepatotoxicity in some cases, and rare more serious events. The clinical literature does not currently support kratom for any specific therapeutic indication.
Practical guidance
For anyone considering use, the consistent guidance from public health authorities is the same. Speak with a clinician first, particularly with any liver disease, heart conditions, mental health conditions, current substance use, or during pregnancy or breastfeeding. Avoid combining with alcohol, opioids, benzodiazepines, or other central nervous system depressants. Be aware that the unregulated market produces meaningful product-to-product variation and that extract products are typically several times more potent than leaf powder.
FAQ
Is kratom legal in the United States? Federal status is unscheduled. Several states have banned the substance; others have enacted Kratom Consumer Protection Acts.
Has the FDA approved kratom for any use? No.
What is the difference between powder and extract? Powder is dried, milled leaf. Extracts concentrate the alkaloid fraction and are typically several times more potent.
Should I speak with a clinician first? Yes. Public-health authorities consistently recommend clinical consultation before use.